Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment for women news


From To
The New Face of HIV and Treating the 'Hardly Reached'

Physicians, scientists, government agencies, and companies are questioning whether the way they've always recruited for clinical trials still serves patients.

20 July 2019
Medscape (requires free registration)
Efavirenz in HIV-positive pregnant women, risk of neurological condition in children

Researchers found children of women whose ART regimen included efavirenz were 60 percent more likely to develop a neurological condition, such as microcephaly (small head), seizures (from a high fever or other cause) and eye abnormalities than children whose mothers took other ART medications.

05 October 2018
IDSA press release
Lynne Mofenson, M.D., Explains the Dolutegravir Risks for People With HIV Who Want to Get Pregnant

Lynn Mofenson, M.D., who is a researcher with the Elizabeth Glaser Pediatric AIDS Foundation, explains what is known about the potential risk of neural tube defects when dolutegravir is used around the time of conception.

15 August 2018
The Body PRO
FDA says Prezcobix should not be given to pregnant women

Darunavir/cobicistat — marketed as Prezcobix (Janssen) in the United States — should not be given to pregnant women with HIV because of substantially lower exposures of the two medications during pregnancy, the FDA said. The agency updated the label for the once-daily, fixed-dose tablet to reflect the change, which it said was based on data from a small clinical trial involving pregnant women.

11 June 2018
Healio (requires free registration)
BHIVA statement on Potential Safety Signal in Infants Born to Women Conceiving on Dolutegravir

The BHIVA HIV in Pregnancy Guidelines Writing group makes the following recommendations: all women wishing to conceive should be started on folic acid 5mg OD regardless of their cART regimen; all women commencing DTG should have a negative pregnancy test prior to initiation and ongoing method of contraception documented; we advise a review of all patient records of women aged up to 50yo on DTG with regards to conception plans, documented method of contraception and current pregnancy status; we recommend that women at risk of pregnancy be contacted by their clinic to discuss the DTG safety report, which should be clearly documented, and the woman seen in person if pregnant.

23 May 2018
British HIV Association
Potential safety issue affecting women living with HIV using dolutegravir at the time of conception

WHO advises that countries and ministries follow the existing 2016 WHO Consolidated ARV Guidelines, and consider the following: Pregnant women who are taking DTG should not stop their ARV therapy and should speak with their health provider for additional guidance. If other first‐line ARVs cannot be used in women of childbearing age, DTG may be considered in cases where consistent contraception can be assured.

21 May 2018
World Health Organization
Women and HIV: invisible no longer

Women and HIV: Invisible No Longer was a one-year project led by Sophia Forum and Terrence Higgins Trust. It aimed to set out clear recommendations for policy and service development to ensure that greater focus is given to women affected by HIV.

09 April 2018
Terrence Higgins Trust
NIH Begins Large HIV Treatment Study in Pregnant Women

The National Institutes of Health has launched a large international study to compare the safety and efficacy of three antiretroviral treatment regimens for pregnant women living with HIV and the safety of these regimens for their infants. The study will evaluate the current preferred first-line regimen for pregnant women recommended by the World Health Organization (WHO) and two regimens containing newer antiretroviral drugs that are becoming more widely used.

24 January 2018
NIAID press release
The Best Antiretroviral Therapy for Pregnant Women? The Controversy Continues

There's considerable controversy in an area of HIV medicine that one would think should be all but solved by now. It's what HIV treatment we should give pregnant women.

18 October 2017
The Body PRO
Alice Welbourn: WHO and the rights of women living with HIV

A recent set of articles on HIV in pregnancy, published by The BMJ and BMJ Open, raises concerns that some combination anti-retroviral therapies (cARTs) may harm babies. This highlights the need for changes to current WHO practice towards pregnant women living with HIV, which is no doubt well-intentioned but ill thought-out.

12 September 2017
BMJ Opinion
← First12345Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.